ArticleBMC cancer2010
Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.Scientific reports · 2016Trial
- Metabolomics of Prostate Cancer and Clinical Profiles Following Radiotherapy: Need for a Precision Phylometabolomics Approach.Diagnostics (Basel, Switzerland) · 2025Article
- Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma.Diagnostics (Basel, Switzerland) · 2023Review
- Carbon Ion Radiotherapy Induce Metabolic Inhibition After Functional Imaging-Guided Simultaneous Integrated Boost for Prostate Cancer.Frontiers in oncology · 2022Article
- Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.Frontiers in cellular and infection microbiology · 2021Article
- Identification of Novel Serum Metabolic Biomarkers as Indicators in the Progression of Intravenous Leiomyomatosis: A High Performance Liquid Chromatography-Tandem Mass Spectrometry-Based Study.Frontiers in cell and developmental biology · 2021Article
- Cerebrospinal fluid-based metabolomics to characterize different types of brain tumors.Journal of neurology · 2020Article
- The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study.Molecules (Basel, Switzerland) · 2019Article
- Metabolomics-Based Biosignatures of Prostate Cancer in Patients Following Radiotherapy.Omics : a journal of integrative biology · 2019Article
- Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.Cancer research and treatment · 2018Article
- Serum NMR metabolomics to differentiate haematologic malignancies.Oncotarget · 2018Article
- Article
- Article
- Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin's Lymphoma Patients.Cell journal · 2017Article
- Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.Oncotarget · 2016Article
- Low-mass-ion discriminant equation (LOME) for ovarian cancer screening.BioData mining · 2016Article
- Identification of oxidized phospholipids in bronchoalveolar lavage exposed to low ozone levels using multivariate analysis.Analytical biochemistry · 2015Article
- Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting.Blood cancer journal · 2015Article
- EPMA position paper in cancer: current overview and future perspectives.The EPMA journal · 2015Article
- Identification of hypoxanthine and phosphoenolpyruvic Acid as serum markers of chemoradiotherapy response in locally advanced rectal cancer.Cancer research and treatment · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-Hodgkin lymphoma (NHL) is a hematologic malignancy for which good diagnostic markers are lacking. Despite continued improvement in our understanding of NHL, efforts to identify diagnostic markers have yielded dismal results. Here, we translated low-mass-ion information in urine samples from patients with NHL into a diagnostic marker.
methodsTo minimize experimental error, we tested variable parameters before MALDI-TOF analysis of low-mass ions in urine. Urine from 30 controls and 30 NHL patients was analyzed as a training set for NHL prediction. All individual peak areas were normalized to total area up to 1000 m/z. The training set analysis was repeated four times. Low-mass peaks that were not affected by changes in experimental conditions were collected using MarkerView software. Human Metabolome Database (HMDB) searches and ESI LC-MS/MS analyses were used to identify low-mass ions that exhibited differential patterns in control and NHL urines. Identified low-mass ions were validated in a blinded fashion in 95 controls and 66 NHL urines to determine their ability to discriminate NHL patients from controls.
resultsThe 30 highest-ranking low-mass-ion peaks were selected from the 60-urine training set, and three low-mass-ion peaks with high intensity were selected for identification. Of these, a 137.08-m/z ion showed lower mass-peak intensity in urines of NHL patients, a result that was validated in a 161-urine blind validation set (95 controls and 66 NHL urines). The 130.08-m/z ion was identified from HMDB searches and ESI LC-MS/MS analyses as hypoxanthine (HX). The HX concentration in urines of NHL patients was significantly decreased (P < 0.001) and was correlated with the mass-peak area of the 137.08-m/z ion. At an HX concentration cutoff of 17.4 microM, sensitivity and specificity were 79.2% and 78.4%, respectively.
conclusionsThe present study represents a good example of low-mass-ion profiling in the setting of disease screening using urine. This technique can be a powerful non-invasive diagnostic tool with high sensitivity and specificity for NHL screening. Furthermore, HX identified in the study may be a useful single urine marker for NHL screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.